# 1. Financial Performance ## A. Key Figures * Revenue from Operations: ₹307.9 Cr Q2 FY26 (+16.9% YoY, +10.6% QoQ) * **Gross Profit:** **₹22.9 Cr** Q2 FY26 (+34.2% YoY, +9.8% QoQ) · **Gross Margin:** **7.5%** (+100 bps YoY) * **Net Capital Raised:** **₹222 Cr** (Sastasundar Healthbuddy Ltd) · **Free Treasury:** **₹445 Cr** * **Total Treasury:** **₹400 Cr** (subsidiaries, excl. buyback) · **Treasury Income:** **₹40–50 Cr** annual * **Annual Capex:** **₹40–50 Cr** (fully internally funded) ## B. Revenue Growth * **Resilient Top-Line Performance:** Revenue growth reflects **strong double-digit momentum** driven by disciplined execution and operational scaling. ## C. Gross Profit & Margin * **Margin Expansion Achieved:** Gross margin improved significantly despite modest profit growth, indicating **favorable cost leverage** and operational efficiency gains. ## D. Balance Sheet Strength * **Enhanced Ownership & Capital Efficiency:** Strategic buyback increased ownership in Sastasundar Healthbuddy from 14% to 89%, simplifying structure and unlocking control benefits. * **Robust Liquidity Position:** Free treasury nearly doubles net capital raised, underscoring **exceptional capital efficiency** and de-risked growth funding. * **Self-Sustaining Growth Model:** Treasury income alone covers expansion costs, positioning the company for **PAT positivity from next year**. ## E. Cash Flow & Capex * **Capital Discipline Maintained:** Targeted annual capex in technology and automation fully funded through internal accruals, with **no external financing plans**. --- # 2. Business Model & Platform ## A. Key Figures * **Inventory Level:** **30 days** combined B2B/B2C inventory due to shared procurement and warehousing * **ROCE Target:** **50%–60%** projected at scale over 4–5 years ## B. B2B & B2C Integration * **Unified Platform Infrastructure:** B2B and B2C operations are integrated through shared procurement and warehousing, enabling **30-day inventory turnover** and operational synergies. * **Ecosystem-Driven Model:** Operates a multi-layered platform combining B2B, B2C, health data, AI, and stakeholder engagement to create a closed-loop healthcare ecosystem. ## C. Scalability & Capital Efficiency * **High Leverage, Low Capital Model:** Targets **50%–60% ROCE** with minimal capital deployment, underpinned by automation, operating leverage, and a shift toward asset-light service offerings. * **Scalable Dual-Platform Strategy:** Sastasundar (B2C) and RetailerShakti (B2B) form a capital-efficient foundation for national expansion, with long-term focus extending to FY29–30. * **Asset-Light Evolution:** Partner-managed inventory model enables transition to a **low-capital, high-margin service business**, reducing balance sheet intensity. ## D. Ecosystem Expansion * **New Revenue Streams:** Expanding into SaaS and Warehouse-as-a-Service for beauty, personal care, and surgical care sectors using existing logistics and platform infrastructure. * **Tech-Enabled Distribution Solutions:** Aims to solve India’s fragmented distribution challenges through data-driven supply chain services, monetizing logistics and data capabilities beyond core healthcare. --- # 3. Product & Segment Performance ## A. Key Figures * **RetailerShakti Revenue:** **₹267.8 Cr** (Q2) (~13% YoY) · **~₹1,071.2 Cr** annualized run rate * RetailerShakti Scale: Grew from **₹10-odd Cr** to **~₹270-odd Cr/month** in 18-odd months * **Sastasundar Legacy Revenue:** **₹500 Cr** (pre-Flipkart handover) * **Diagnostics Pricing:** **~50% lower** than larger players * **Private Label Savings:** Up to **60%** for customers ## B. Sastasundar B2C * **Accelerating Growth Trajectory:** B2C segment delivered robust momentum with strong double-digit expansion, driven by new customer acquisition, higher order frequency, and increased ticket sizes. * **Path to Profitability:** Contribution margin positivity expected next year, with EBITDA breakeven projected for FY28–FY29, supported by scalable unit economics. * **Value Replication Strategy:** Company aims to rebuild legacy Sastasundar revenue base within 18 months and replicate **INR1,100 Cr app valuation** through targeted **INR150 Cr investment**, underscoring digital asset leverage. * **Digital Ecosystem Expansion:** Sastasundar podcast and new daily video series on holistic well-being are monetizing early, enhancing brand engagement and digital IP value. ## C. RetailerShakti B2B * **Breakeven Achieved, Margin Expansion Ahead:** B2B arm reached breakeven in Q4 and is on track for EBITDA positivity next quarter, with a targeted **1% full-year margin** in FY26. * **Exponential Scale-Up:** Revenue surged from ₹10 Cr to ~₹270 Cr/month in just 18 months, reflecting product-market fit and efficient execution. * **Sustainable Differentiation:** Management asserts structural efficiency advantage over peers like Entero, citing superior business model design despite lower near-term ROE. * **Gross Margin Upside:** Margin expansion observed and expected to continue, validating operational maturity and pricing power. ## D. JITO Clinic & Diagnostics * **Human-Centric Healthcare Model:** Targets 100 crore underserved Indians, particularly 30 crore with chronic conditions, by eliminating wage loss, wait times, and dignity barriers via at-home teleconsultation and diagnostics. * **Integrated Care Delivery:** Clinics offer AI-assisted consultations, affordable diagnostics (~50% cheaper), and JITO-branded generics, addressing 99% of primary care needs in a seamless, low-cost model. ## E. Private Label & New Categories * **Margin-Enhancing Diversification:** Expansion into beauty, personal care, nutraceuticals, and pet care leverages existing infrastructure with minimal incremental cost, boosting gross margins via fixed cost absorption. * **Strategic Brand Segmentation:** Launch of **"Mobat [Mohbbat]"** as a dedicated branded channel within the app ensures clear separation of non-pharma products, preserving pharmaceutical brand integrity. * **Logistics-Led Assortment Discipline:** Product expansion limited to **lightweight items**; heavyweight categories excluded to maintain operational efficiency and delivery economics. --- # 4. Capacity & Fulfillment ## A. Key Figures * **Warehouse Capacity:** **Doubled** in Baruipur via automation · **Tripling** within 3 months * **Fulfillment Capacity:** Set to **double** with automation in FC and logistics * **AI Impact:** **Tripled** warehouse capacity without incremental capex ## B. Warehouse Expansion * **Regional Scalability:** Strategic warehouse rollout in **Lucknow and Udaipur** to expand footprint across Northern and Western India, with Udaipur serving as a stealth entry point into **Ahmedabad and interior Gujarat**. * **Pharmacy Digitization:** App-driven **pharmacy-level adoption** underway to reduce **inventory days** through streamlined reorder workflows. ## C. Automation Gains * **AI-Driven Efficiency:** AI automation has **tripled capacity** by digitizing core workflows—**script labeling, order picking, logistics routing**—while significantly lowering labor dependency. * **Integrated Automation:** Retailer app integration with **RetailerShakti** enables end-to-end order automation, enhancing fulfillment speed and accuracy. --- # 5. Customer & Distribution ## A. Key Figures * **Retailer Target:** **55,000** retailers by end of next fiscal (from ~40,000) * **HealthBuddy Count & Run Rate:** **260** HealthBuddies generating **₹40 Cr** quarterly run rate · Target: **360** HealthBuddies for **₹100 Cr** quarterly run rate by Mar-26 ## B. Retailer Acquisition * **Scalable Distribution Push:** Ambitious plan to add **15,000 retailers annually**, leveraging existing B2C trust to re-engage dormant app users and expand footprint. * **Value-Added Engagement:** App rollout expected to boost **wallet share, retention, and order stickiness** among partner pharmacies via streamlined procurement and inventory tools. ## C. HealthBuddy Count * **High-Margin Channel Expansion:** HealthBuddy network on track to scale from 260 to 360 members over 18 months, targeting a near-tripling of quarterly revenue run rate. --- # 6. Technology & AI Impact ## A. Key Figures * **AI Cost Savings:** **50% reduction** in call center staffing needs due to automated monitoring * **AI Investment vs. Income:** AI development spend to remain **below treasury income**, supporting path to **PAT positivity** in next fiscal ## B. AI Cost Reduction * **Strategic Cost Focus:** AI and automation prioritized for tangible operational savings, particularly in warehousing and development, with measurable efficiency gains already realized. * **Leveraged Ecosystem:** As a distributor, the company integrates back-end AI from **Google, Microsoft, and ChatGPT** to deliver Indianized solutions at scale. * **Margin Improvement Path:** Sustained investment in concrete AI use cases expected to enhance service levels and drive margin expansion, especially in key regions like **West Bengal**. ## C. Counseling & Diagnostics * **AI-Powered Patient Support:** Development of a multilingual counseling tool using leading AI medical knowledge to improve medication adherence and doctor-patient coordination. * **Enhanced Clinical Workflow:** AI-assisted nurse consultations generate analytical reports for doctors, enabling automated prescription verification and addressing poor self-monitoring of chronic conditions. --- # 7. Risks & Execution Challenges ## A. Key Figures * **Payable Cycle:** **~21 days** (B2B & B2C) * **Receivable Period:** **6–7 days** (contributes to ~20–25 day working capital cycle) * **Working Capital Target:** **3–4% of revenue** (expected in 3–5 years) with **50–100 bps annual improvement** ## B. Startup Operational Risk * **High-Growth, Early-Stage Profile:** Company in building phase with limited capital; investors should expect minor operational hiccups and adjustments over the medium term. * **Long-Term Adoption Curve:** Customer uptake of new technologies anticipated to be gradual, requiring sustained education and behavioral shift. ## C. Geographic Concentration * **High Regional Exposure:** Business remains heavily concentrated in **West Bengal and Eastern India**, with limited diversification to NCR. ## D. Working Capital Volatility * **Near-Term Stability, Long-Term Optimization:** Working capital expected to remain around **6% of sales** for next two years despite expansion-related fluctuations; path set for structural improvement toward negative working capital. * **Expansion-Driven Fluctuations:** New warehouse rollouts in **Udaipur and Lucknow** may cause short-term volatility in working capital metrics. --- # 8. Guidance & Outlook ## A. Key Figures * **Long-Term Revenue Target:** **₹6,000 Cr** by FY29–30 (₹4,000 Cr RetailerShakti + ₹2,000 Cr Sastasundar) * **Profitability Guidance:** Breakeven EBITDA expected in **Mar '26 quarter** · **1% EBITDA margin** targeted for full FY27 ## B. Long-Term Revenue Targets * **Sustained Growth Path:** Management expects current momentum to persist over the next **4–6 quarters**, supported by multi-year investment in Sastasundar. * **Regional Focus with Scale:** Expansion will remain concentrated in **Eastern and Northern India** over the next three years, with no plans to enter Western or South India. * **Scalable Retail Network:** Annual addition of **15,000 retailers** set to continue for **2–3 years**, underpinning geographic and revenue scalability. ## C. Profitability Timeline * **Path to Profitability:** Company on track to achieve **EBITDA breakeven in Mar '26**, marking transition from cash-burning to **profitable growth model**. * **Margin Progression:** Sastasundar expected to reach **contribution margin positivity next year**, while RetailerShakti to drive future EBITDA and PAT. * **Holistic Profitability Model:** PAT positivity to be achieved through operating leverage, treasury income, and cost discipline across business units. ## D. Strategic Expansion Plan * **Growth Acceleration Roadmap:** Strategy centers on scaling via **technology development, fulfillment expansion, AI integration**, and broader product and market reach. * **Systematic Geographic Rollout:** Model validated across **15–20 states** (covering ~50% of India’s market), with focus on deepening penetration before national expansion. * **Vision-Driven Scale:** Long-term mission to deliver healthcare to **140 crore Indians** under "Shatayu Bhava – 100 Years Healthy Living". * **Structural Clarity Ahead:** Merger and demerger plans with holding company to be presented to Board by **31 March 2026**, enabling strategic realignment.